Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market Targets US$ 2.8 Billion Milestone by 2032

The endoscopic retrograde cholangiopancreatography (ERCP) devices market sales is expected to reach US$ 1.5 billion in 2022 and US$ 2.8 billion by 2032 as a result of an increase in cancer incidence worldwide. The market for endoscopic retrograde cholangiopancreatography (ERCP) equipment is anticipated to develop at a compound annual growth rate (CAGR) of 6.2% between 2022 and 2032, according to forecasts by FMI.

The Endoscopic Retrograde Cholangiopancreatography (ERCP) Devices Market is undergoing significant developments, showcasing its pivotal role in diagnostic and therapeutic procedures for pancreatic and biliary disorders. As an integral part of minimally invasive endoscopic techniques, ERCP devices enable healthcare professionals to visualize, diagnose, and treat conditions affecting the pancreas and bile ducts. Continuous advancements in technology are enhancing the precision and effectiveness of these devices, contributing to improved patient outcomes. Stakeholders in the market, including medical device manufacturers and healthcare practitioners, are actively engaged in innovations to address evolving clinical needs and enhance the efficiency of ERCP procedures.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-9658

The market for endoscopic retrograde cholangiopancreatography (ERCP) devices combines fluoroscopic imaging and luminal endoscopy for the diagnosis and treatment of pancreatobiliary system disorders. Endoscopic retrograde cholangiopancreatography (ERCP) devices use a side-view duodenoscopy that is then passed through the oesophagus and stomach into the duodenum’s latter section. Endoscopic retrograde cholangiopancreatography (ERCP) devices are primarily used to collect tissue and cell samples, as well as to treat a blocked pancreatic or bile duct.

The blockage of the ducts could be caused by non-cancerous stones in the duct or by cancer. Endoscopic retrograde cholangiopancreatography (ERCP) imaging tests are used for diagnosis or examination of the pancreatic ducts, as well as the gallbladder, liver, and pancreas. Magnetic resonance cholangiopancreatography and computed tomography machines are alternatives to endoscopic retrograde cholangiopancreatography (ERCP) devices. Endoscopic retrograde cholangiopancreatography (ERCP) devices are used for a variety of procedures such as sphincterotomy, stone removal, stent placement, dilatation, and draining bodily fluids.

Endoscopic Retrograde Cholangiopancreatography (ECRP) Devices Market: Drivers and Restraints-

Over the years, endoscopic retrograde cholangiopancreatography (ECRP) devices have grown in popularity for cancer treatment. During the forecast period, the increasing incidence of benign liver and pancreatic tumours is expected to create appealing market opportunities for endoscopic retrograde cholangiopancreatography (ECRP) devices across regions.

Several ongoing studies for safer use and improved efficiency of these endoscopic retrograde cholangiopancreatography (ECRP) devices, as well as rising government support for R&D, may also drive market growth for endoscopic retrograde cholangiopancreatography (ECRP) devices over the forecast period. Growing awareness of endoscopic retrograde cholangiopancreatography (ECRP) devices, as well as an increase in availability, are expected to drive market growth for ECRP devices.

On the other hand, high endoscopic retrograde cholangiopancreatography (ECRP) device costs and side effects such as post-ERCP pancreatitis, infection, haemorrhage, and allergic reactions associated with cholangiopancreatography procedures are expected to stymie market growth for endoscopic retrograde cholangiopancreatography (ECRP) devices during the forecast period.

Endoscopic Retrograde Cholangiopancreatography (ECRP) Devices Market: Overview

Endoscopic retrograde cholangiopancreatography (ECRP) devices use advanced techniques and thus have a higher rate of serious complications than other endoscopic procedures. As a result, specialised equipment and training are required, and the procedure is carried out for appropriate applications. According to a review by Freeman et al, approximately 500,000 procedures are performed in the United States each year. Endoscopic retrograde cholangiopancreatography (ECRP) devices are frequently used in hospital settings where patients with pancreatic or gallstone disease are admitted.

Tissue sampling or biliary or pancreatic ductal system disease treatment, obstructive jaundice, pancreatitis of unknown cause, suspicion for pancreatic cancer, nasobiliary drainage, manometry for sphincter of Oddi, biliary stenting for leakage and strictures, balloon dilation of ductal strictures and duodenal papill, and drainage of pancreatic pseudocysts are

Endoscopic Retrograde Cholangiopancreatography (ECRP) Devices Market: Region-wise Outlook

The market for endoscopic retrograde cholangiopancreatography (ECRP) devices in North America is expected to grow significantly as a result of increased diagnostic imaging-related research and improved research and development for advanced and safe endoscopic retrograde cholangiopancreatography (ECRP) devices. During the forecast period, improved healthcare infrastructure and expenditure are expected to drive the Europe market for endoscopic retrograde cholangiopancreatography (ECRP) devices.

Growing cholangiopancreatography procedure awareness in China, India, and Japan is expected to fuel the Asia-Pacific market for endoscopic retrograde cholangiopancreatography (ECRP) devices. The constant increase in the number of endoscopic retrograde cholangiopancreatography (ECRP) device manufacturers is expected to drive demand for ECRP devices during the forecast period.

Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-9658

Endoscopic Retrograde Cholangiopancreatography (ECRP) Devices Market: Key Market Participants

A few market participants in the global endoscopic retrograde cholangiopancreatography (ECRP) devices market identified across the value chain include: Olympus Corporation, Boston Scientific Corporation, CONMED Corporation, Cook Medical, Inc., Hobbs Medical, Merit Medical Systems and , TeleMed Systems, Inc.

The endoscopic retrograde cholangiopancreatography (ECRP) devices research report provides a comprehensive assessment of the market and includes thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also includes projections based on an appropriate set of assumptions and methodologies. The endoscopic retrograde cholangiopancreatography (ECRP) devices report analyses and provides information based on market segments such as geography, application, and industry.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Key Companies:
Olympus Corporation
Boston Scientific Corporation
CONMED Corporation
Cook Medical, Inc.
Hobbs Medical,
Merit Medical Systems
TeleMed Systems, Inc.
Fujifilm Holdings Corporation

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube